CA2427617A1 - Medicinal compositions for concomitant use as anticancer agent - Google Patents
Medicinal compositions for concomitant use as anticancer agent Download PDFInfo
- Publication number
- CA2427617A1 CA2427617A1 CA002427617A CA2427617A CA2427617A1 CA 2427617 A1 CA2427617 A1 CA 2427617A1 CA 002427617 A CA002427617 A CA 002427617A CA 2427617 A CA2427617 A CA 2427617A CA 2427617 A1 CA2427617 A1 CA 2427617A1
- Authority
- CA
- Canada
- Prior art keywords
- ring
- salt
- substituent group
- anticancer agent
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- -1 sulfonamide compound Chemical class 0.000 abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005144 gemcitabine hydrochloride Drugs 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 abstract 1
- 229950010538 irinotecan hydrochloride trihydrate Drugs 0.000 abstract 1
- 229960004857 mitomycin Drugs 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising a sulfonamide compound, a sulfonate compound or a salt of them, which is represented by the following formula:
(see formula above) (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group;
W represents a single bond or -CH=CH-; X represents -NH- etc. ;
and Y represents a carbon atom or a nitrogen atom; and Z
represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil;
(4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin;
(7) taxol; and (8) a salt of the above-mentioned (1) to (7).
(see formula above) (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group;
W represents a single bond or -CH=CH-; X represents -NH- etc. ;
and Y represents a carbon atom or a nitrogen atom; and Z
represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil;
(4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin;
(7) taxol; and (8) a salt of the above-mentioned (1) to (7).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-333952 | 2000-10-31 | ||
| JP2000333952 | 2000-10-31 | ||
| PCT/JP2001/009563 WO2002036117A1 (en) | 2000-10-31 | 2001-10-31 | Medicinal compositions for concominant use as anticancer atent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2427617A1 true CA2427617A1 (en) | 2003-04-29 |
| CA2427617C CA2427617C (en) | 2009-10-06 |
Family
ID=18809950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002427617A Expired - Fee Related CA2427617C (en) | 2000-10-31 | 2001-10-31 | Medicinal compositions for concomitant use as anticancer agent |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20040002505A1 (en) |
| EP (1) | EP1331005B1 (en) |
| JP (1) | JP4167898B2 (en) |
| KR (1) | KR100829875B1 (en) |
| CN (1) | CN1196484C (en) |
| AT (1) | ATE322264T1 (en) |
| AU (2) | AU1099302A (en) |
| CA (1) | CA2427617C (en) |
| DE (1) | DE60118590T2 (en) |
| NZ (1) | NZ524975A (en) |
| TW (1) | TWI283575B (en) |
| WO (1) | WO2002036117A1 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3712393B2 (en) | 2000-10-20 | 2005-11-02 | エーザイ株式会社 | Nitrogen-containing aromatic ring derivatives |
| WO2004080462A1 (en) * | 2003-03-10 | 2004-09-23 | Eisai Co., Ltd. | c-Kit KINASE INHIBITOR |
| KR20060007368A (en) * | 2003-05-08 | 2006-01-24 | 에자이 가부시키가이샤 | Pharmaceutical compositions comprising N- (3-chloro-lH-indol-7-yl) -4-sulfamoylbenzenesulfonamide and inhibitors of cell proliferation |
| KR20060120644A (en) * | 2003-09-10 | 2006-11-27 | 에자이 가부시키가이샤 | Determination of sulfonamide-containing indole compound and preparation method thereof |
| US20070037854A1 (en) * | 2003-09-10 | 2007-02-15 | Kenji Hayashi | Process for preparing sulfonamide-containing indole compounds |
| WO2005044788A1 (en) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | Urea derivative and process for producing the same |
| WO2005066135A2 (en) * | 2003-12-29 | 2005-07-21 | Sepracor Inc. | Pyrrole and pyrazole daao inhibitors |
| CA2557504C (en) * | 2004-02-26 | 2020-12-01 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| KR20070053205A (en) | 2004-09-17 | 2007-05-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Medicinal composition |
| EP1859797A4 (en) * | 2005-02-28 | 2011-04-13 | Eisai R&D Man Co Ltd | Novel concomitant use of sulfonamide compound with anti-cancer agent |
| CN1313104C (en) * | 2005-05-27 | 2007-05-02 | 中国科学院南海海洋研究所 | Anticancer medicine composition with synergistic bupleurum root and polymyxin |
| WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| WO2007015569A1 (en) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Method for assay on the effect of vascularization inhibitor |
| AU2006285673B2 (en) * | 2005-09-01 | 2010-12-02 | Eisai R&D Management Co., Ltd. | Method for preparation of pharmaceutical composition having improved disintegratability |
| KR101353763B1 (en) | 2005-11-07 | 2014-01-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR |
| WO2007061130A1 (en) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| CN101426372A (en) * | 2006-01-06 | 2009-05-06 | 塞普拉柯公司 | Tetralone-based monoamine reuptake inhibitors |
| NZ569630A (en) | 2006-01-06 | 2011-09-30 | Sepracor Inc | Cycloalkylamines as monoamine reuptake inhibitors |
| ES2643602T3 (en) | 2006-03-31 | 2017-11-23 | Sunovion Pharmaceuticals Inc. | Amines and chiral |
| CN101443009A (en) * | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | Antitumor agent for thyroid cancer |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US20080058395A1 (en) * | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
| CN101511793B (en) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | Antineoplastic agents against undifferentiated gastric cancer |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| AU2008206039A1 (en) * | 2007-01-18 | 2008-07-24 | Sepracor Inc. | Inhibitors of D-amino acid oxidase |
| AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| JP5420534B2 (en) | 2007-05-31 | 2014-02-19 | サノビオン ファーマシューティカルズ インク | Phenyl-substituted cycloalkylamines as monoamine reuptake inhibitors |
| WO2009060945A1 (en) * | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CA2713930A1 (en) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
| CN101584696A (en) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | Composition containing quinazoline derivatives, preparation method and use |
| WO2010017418A1 (en) * | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| CN102958523B (en) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | Antitumor agent using compounds having kinase inhibitory effect in combination |
| MX2013009931A (en) | 2011-04-18 | 2013-10-01 | Eisai R&D Man Co Ltd | Therapeutic agent for tumor. |
| JP6038128B2 (en) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | A biomarker for predicting and evaluating the reactivity of thyroid and renal cancer subjects to lenvatinib compounds |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| WO2014185540A1 (en) | 2013-05-14 | 2014-11-20 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| EP3094635B1 (en) | 2014-01-17 | 2018-07-04 | Oncoral Pharma ApS | Solid oral dosage form of irinotecan for the treatment of cancer |
| SG10202100272RA (en) | 2014-08-28 | 2021-02-25 | Eisai R&D Man Co Ltd | High-purity quinoline derivative and method for manufacturing same |
| JP7113619B2 (en) * | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | Treatment of breast cancer with liposomal irinotecan |
| MX385403B (en) | 2015-02-25 | 2025-03-18 | Eisai R&D Man Co Ltd | METHOD FOR SUPPRESSING THE BITTERNESS OF A QUINOLINE DERIVATIVE. |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| KR102587702B1 (en) | 2015-08-20 | 2023-10-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | tumor treatment |
| CA2992789A1 (en) | 2015-08-20 | 2017-02-23 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| RU2747124C2 (en) | 2015-08-21 | 2021-04-28 | Ипсен Биофарм Лтд. | Methods of treating metastatic pancreatic cancer by a combination therapy comprising administering irinotecan and oxaliplatin |
| SG10201912338RA (en) | 2016-11-02 | 2020-02-27 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| MX2019013014A (en) | 2017-05-16 | 2020-08-06 | Eisai R&D Man Co Ltd | Treatment of hepatocellular carcinoma. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1221533C (en) * | 1993-09-10 | 2005-10-05 | 卫材株式会社 | Heterobicyclic sulfonamide derivative and sulfonic ester derivative |
| JP3545461B2 (en) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | Bicyclic heterocycle-containing sulfonamide derivatives |
| JPH09208571A (en) * | 1996-02-02 | 1997-08-12 | Takeda Chem Ind Ltd | Alkylidenecyclohexane derivative |
| JP2000143635A (en) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | Arterialization inhibitor |
| JP2000247949A (en) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | Indole compound containing sulfonamide |
| US6911306B1 (en) * | 1999-10-18 | 2005-06-28 | Emory University | TMS1 compositions and methods of use |
| DK1296714T3 (en) * | 2000-06-22 | 2009-12-07 | Coley Pharm Gmbh | Combination of CpG and antibodies directed against CD19, CD20, CD22 or CD40 for the treatment or prevention of cancer |
-
2001
- 2001-10-30 TW TW090126893A patent/TWI283575B/en active
- 2001-10-31 WO PCT/JP2001/009563 patent/WO2002036117A1/en active IP Right Grant
- 2001-10-31 AT AT01978983T patent/ATE322264T1/en not_active IP Right Cessation
- 2001-10-31 CA CA002427617A patent/CA2427617C/en not_active Expired - Fee Related
- 2001-10-31 AU AU1099302A patent/AU1099302A/en active Pending
- 2001-10-31 DE DE60118590T patent/DE60118590T2/en not_active Expired - Lifetime
- 2001-10-31 AU AU2002210993A patent/AU2002210993B2/en not_active Ceased
- 2001-10-31 US US10/381,909 patent/US20040002505A1/en not_active Abandoned
- 2001-10-31 NZ NZ524975A patent/NZ524975A/en unknown
- 2001-10-31 KR KR1020037004463A patent/KR100829875B1/en not_active Expired - Fee Related
- 2001-10-31 JP JP2002538929A patent/JP4167898B2/en not_active Expired - Fee Related
- 2001-10-31 CN CNB018183581A patent/CN1196484C/en not_active Expired - Fee Related
- 2001-10-31 EP EP01978983A patent/EP1331005B1/en not_active Expired - Lifetime
-
2003
- 2003-05-08 US US10/431,569 patent/US20030215523A1/en not_active Abandoned
-
2004
- 2004-05-06 US US10/839,222 patent/US20040224972A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1331005A4 (en) | 2004-12-22 |
| JPWO2002036117A1 (en) | 2004-03-11 |
| US20040002505A1 (en) | 2004-01-01 |
| CN1196484C (en) | 2005-04-13 |
| KR100829875B1 (en) | 2008-05-16 |
| ATE322264T1 (en) | 2006-04-15 |
| JP4167898B2 (en) | 2008-10-22 |
| WO2002036117A1 (en) | 2002-05-10 |
| CN1473041A (en) | 2004-02-04 |
| DE60118590T2 (en) | 2007-01-18 |
| NZ524975A (en) | 2004-11-26 |
| CA2427617C (en) | 2009-10-06 |
| US20040224972A1 (en) | 2004-11-11 |
| EP1331005B1 (en) | 2006-04-05 |
| TWI283575B (en) | 2007-07-11 |
| AU2002210993B2 (en) | 2006-12-07 |
| US20030215523A1 (en) | 2003-11-20 |
| DE60118590D1 (en) | 2006-05-18 |
| KR20030046475A (en) | 2003-06-12 |
| AU1099302A (en) | 2002-05-15 |
| EP1331005A1 (en) | 2003-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2427617A1 (en) | Medicinal compositions for concomitant use as anticancer agent | |
| CA2415010A1 (en) | Propane-1,3-dione derivatives useful as gnrh receptor antagonist | |
| CA2414018A1 (en) | 2-aminocarbonyl-9h-purine derivatives | |
| IL154350A (en) | Phenylalanine derivatives and pharmaceutical compositions containing them | |
| EP1253142A4 (en) | Compounds exhibiting thrombopoietin receptor agonism | |
| CA2560510A1 (en) | N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides | |
| EA200300412A1 (en) | PHARMACEUTICAL ACTIVE DERIVATIVES OF SULPHONAMIDE, CONTAINING AS LYPOPHIL, SO AND IONIZABLE FRAGMENTS, AS AN INHIBITORS JUN-PROTEINKINAZ | |
| KR900002784A (en) | Pharmaceutical binding agents for use in antitumor therapy | |
| CA2413313A1 (en) | Antitumor effect potentiators | |
| EP1008588A4 (en) | 11,15-o-dialkylprostaglandin e derivatives, process for producing the same, and drugs containing the same as the active ingredient | |
| MXPA02011974A (en) | Substituted quinazoline derivatives and their use as inhibitors. | |
| GB0206860D0 (en) | Compounds | |
| IL174665A0 (en) | Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same | |
| CA2337825A1 (en) | Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions | |
| WO2002048148A3 (en) | Pyrazolopyridine derivatives | |
| CO5580767A2 (en) | INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE | |
| WO2001091797A3 (en) | Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds | |
| IL313466A (en) | CREB-binding protein (CBP) inhibition | |
| HK1099200A1 (en) | Anti-inflammatory agents | |
| WO2003049690A3 (en) | Hiv integrase inhibitors | |
| EP1568382A4 (en) | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER | |
| WO2003053971A8 (en) | Pyridoquinoxaline antivirals | |
| WO2003049676A3 (en) | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer | |
| CA2140927A1 (en) | Platelet aggregation inhibitors | |
| WO2007058568A3 (en) | Salts of 9-oxoacridine-10-acetic acid with 1-alkylamino-1-desoxy-polyols |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |